TGTX stock rises on positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis. See what's next for TG Therapeutics.

TGTX stock rises on positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis. See what's next for TG Therapeutics.

TG Therapeutics shares are trading higher on Wednesday as positive topline Phase 1 data fuels fresh optimism around pipeline expansion.